v3.25.4
Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations
12 Months Ended
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]  
Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations
The Company attributes revenues to geographical region based upon where the services are performed. The following tables represent revenues by geographical region and reportable segment for the years ended December 31, 2025, 2024 and 2023:

December 31, 2025
(in millions)Technology & Analytics SolutionsResearch & Development SolutionsContract Sales & Medical SolutionsTotal
Revenues:
Americas$3,363 $4,105 $277 $7,745 
Europe and Africa2,646 2,273 266 5,185 
Asia-Pacific617 2,518 245 3,380 
Total revenues$6,626 $8,896 $788 $16,310 

December 31, 2024
(in millions)Technology & Analytics SolutionsResearch & Development SolutionsContract Sales & Medical SolutionsTotal
Revenues:
Americas$3,182 $3,894 $280 $7,356 
Europe and Africa2,397 2,304 219 4,920 
Asia-Pacific581 2,329 219 3,129 
Total revenues$6,160 $8,527 $718 $15,405 

December 31, 2023
(in millions)Technology & Analytics SolutionsResearch & Development SolutionsContract Sales & Medical SolutionsTotal
Revenues:
Americas$3,091 $4,157 $304 $7,552 
Europe and Africa2,156 2,103 200 4,459 
Asia-Pacific615 2,135 223 2,973 
Total revenues$5,862 $8,395 $727 $14,984 

When attributing revenues to individual countries based upon where the services are performed, no individual country, except for the United States, accounted for 10% or more of total revenues for the years ended December 31, 2025, 2024 and 2023. For the years ended December 31, 2025, 2024 and 2023, revenues in the United States accounted for approximately 42%, 42%, and 45% of total revenues, respectively, using this revenue attribution approach.

No individual customer represented 10% or more of total revenues for the years ended December 31, 2025, 2024 and 2023.

Transaction Price Allocated to the Remaining Performance Obligations

As of December 31, 2025, approximately $34.2 billion of revenues are expected to be recognized in the future from remaining performance obligations. The Company expects to recognize revenues on approximately 30% of these remaining performance obligations over the next twelve months, on approximately 85% over the next five years, with the balance recognized thereafter. Most of the Company's remaining performance obligations where revenues are expected to be recognized beyond the next twelve months are for service contracts for clinical research in the Company's Research & Development Solutions segment. The customer contract transaction price allocated to the remaining performance obligations differs from backlog in that it does not include wholly unperformed contracts under which the customer has a unilateral right to cancel the arrangement.